Widely distributed vaccine will produce herd immunity
Covid-19 vaccines available in the U.S. and India by the beginning of 2021 will start to form herd immunity. By the middle of the year, target immunity figures will be met.
< (1 of 3) Next argument >
A coronavirus vaccine would drastically reduce the herd immunity threshold—the percentage of the population that needs to be infected or contact the disease to gain herd immunity. In data collected from a U.S. Food and Drug Administration survey, the consulting firm McKinsey and Company found that a vaccine with moderate effectiveness would still reduce the herd immunity threshold to 30 or even 20 percent.  For context, without a vaccine, the U.S. is currently at a 2.2% infection rate, the UK has a less than 1% infection rate, and Brazil has an infection rate of about 2.5%. Scientists have estimated that the coronavirus herd immunity threshold could be as low as 43% without a vaccine, but that would involve nearly half of the population having been infected with the virus. A vaccine will drastically lower that percentage. Health officials in the U.S. and India have estimated that a vaccine for the virus will be available by early 2021, with the Union Health Minister Harsh Vardhan saying that one in five people will be vaccinated by July. Dr. Anthony Fauci, one of Americas most famed disease analysts, said that while a vaccine could be available by January, it will not be administered to large portions of the population until the middle of next year. If coronavirus case counts continue to steadily dimish, a new vaccine will stop the pandemic by July of 2021.
The likelihood people will actually take a vaccine is still up in the air. While a vaccine could help curb the virus by decreasing the herd immunity threshold, a recent poll shows 49 percent of Americans said they would definitely not take a COVID-19 vaccine. 
Rejecting the premises